CHARLES F. SCHIFFER, M.D.; JAMES F. BURKE JR., M.D.; ANATOLE BESARAB, M.D.; NORMAN LASKER, M.D., F.A.C.P.; MICHAEL L. SIMENHOFF, M.D., M.R.C.P.
This content is PDF only. Please click on the PDF icon to access.
The importance of the amylase/creatinine clearance fraction (Cam/Ccr) in differentiating acute pancreatitis from the hyperamylasemia of renal failure was first shown in 1969 by Levitt, Rapoport, and Cooperbrand (1). The specificity of this ratio in acute pancreatitis was recently documented by Warshaw and Fuller (2). However, there have been other studies suggesting an increased Cam/Ccr in situations other than acute pancreatitis, such as diabetic ketoacidosis or extensive burns (3). Because Levitt's paper (1) used patients with mild renal failure, we elected to ascertain the extent to which the Cam/Ccr would apply in patients on chronic hemodialysis with severe renal failure.
SCHIFFER CF, BURKE JF, BESARAB A, LASKER N, SIMENHOFF ML. Amylase/Creatinine Clearance Fraction in Patients on Chronic Hemodialysis. Ann Intern Med. 1977;86:65–66. doi: 10.7326/0003-4819-86-1-65
Download citation file:
Published: Ann Intern Med. 1977;86(1):65-66.
Nephrology, Renal Replacement Therapy.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use